Analisis Efektivitas Biaya Penggunaan Antihipertensi pada Pasien Hipertensi dengan Komplikasi Diabetes Melitus Tipe 2 di RSP Prof Dr Chairuddin Panusunan Lubis Medan

Abstract

Background: According to the Basic Health Research in 2018, there was an increase in the prevalence of hypertension from 27.8% in 2013 to 34.1% in 2018. The economic impact of alternative drug therapies or other health interventions in a comprehensive manner requires pharmacoeconomic analysis. One of the pharmacoeconomic methods used to assess and select the most cost effective interventions across several therapeutic options uses cost effectiveness analysis (CEA). Objective: The purpose of this study was to determine the antihypertensive therapy model and analyze the cost-effectiveness among antihypertensive therapy models in hypertensive patients with or without complications of type 2 diabetes mellitus hospitalized at RSP Prof dr Chairuddin Panusunan Lubis Medan. Method: This research was non-experimental used a retrospective cohort study. Data were obtained from the medical records of hypertensive patients with or without complications of type 2 diabetes mellitus hospitalized at RSP Prof. Dr. Chairuddin Panusunan Lubis Medan period of January 2022 - December 2023. The Cost Effective Ratio (CER) and Incremental Cost Effective Ratio (ICER) methods were used to analyze the use of the most cost effective antihypertensives. Result: This study obtained 25 patients who met the inclusion criteria which were then used as data sources. Most of them were female (68%), with the majority age group 40 - 60 years (68%). The calculation of the CER value shows that the lowest CER value is obtained by the amlodipine + candesartan therapy model (Rp. 6.013), and based on the calculation of the ICER value, the lowest ICER value is obtained by amlodipine + candesartan (Rp.-2.653). Conclusion: This study shows that the most cost-effective antihypertensive therapy model in hypertensive disease patients with or without type 2 diabetes mellitus is amlodipine + candesartan.